Kaleido Biosciences (OTC:KLDO) Stock, Quote.Headers.trade-ideas

Kaleido Biosciences

Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.

Biotech

Earnings

News

Penny Stocks

Small Cap

General

ANTX

ISRG

KLDO

LYRA

OCUL

PSTV

REGN

SRRA

TGTX

Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.

The Week Ahead In Biotech (April 17-April 23): J&amp;J, Abbott Earnings, Adcom Test For TG Therapeutics And More

Health Care

Movers

Trading Ideas

Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why

Price Target

Analyst Ratings

Kaleido Biosciences Inc (NASDAQ: KLDO) halted work on a planned phase 2 trial in chronic obstructive pulmonary disease (COPD) and 

Kaleido Halts Upcoming Phase 2 COPD Trial, Piper Sandler Cuts Price Target

KALEIDO BIOSCIENCES INC by Kaleido Biosciences, Inc.

Kaleido Biosciences Inc

Biotech stocks retreated in the week ending&nbsp;April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.
Lyra Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyra#NASDAQ">LYRA</a>) was among the biggest gainers of the week following the completion of a $100.5 million private placement. Sierra Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srra#NASDAQ">SRRA</a>) also advanced strongly after it announced <a href=" https://www.benzinga.com/general/biotech/22/04/26607770/glaxosmithkline-scoops-up-rare-cancer-focused-sierra-oncology-in-1-9b-cash-deal"> a deal to be acquired </a> by GlaxoSmithKline plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gsk#NYSE">GSK</a>) for $1.9 billion.
Meanwhile, Kaleido Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kldo#NASDAQ">KLDO</a>) plunged after disclosing in a filing that it is shuttering operations. The microbiome therapeutic-focused biopharma was facing a cash crunch and clinical setbacks.
Regeneron Pharmaceuticals, Inc.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>) communicated the Food and Drug Administration&#39;s <a href=" https://www.benzinga.com/general/biotech/22/04/26633719/fda-extends-review-period-for-regenerons-covid-19-antibody-therapy"> decision to delay granting full approval </a>of its antibody cocktail REGEN-COV<a href=" https://www.benzinga.com/general/biotech/22/04/26633719/fda-extends-review-period-for-regenerons-covid-19-antibody-therapy"> </a> as a prophylactic treatment for COVID-19.
Here are the key catalysts that could impact trading in biotech stocks in the unfolding week:
<h3>Conferences</h3>
2022 American Society of Cataract and Refractive Surgery, or ASCRS, Annual Meeting: April 23-26, in Washington, D.C.
2022 Tandem Meetings &ndash; Transplantation &amp; Cellular Therapy Meetings Of American Society for Transplantation and Cellular Therapy, or ASTCT, and Center for International Blood and Marrow Transplant Research, or CIBMTR: April 23-26, in Salt Lake City, Utah
Related Link: <a href="https://www.benzinga.com/general/biotech/22/04/26390771/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates">Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>
<h3>Adcom Calendar</h3>
FDA&#39;s Oncologic Drugs Advisory Committee is scheduled to meet on Friday, April 22 to discuss TG Therapeutics, Inc.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgtx#NASDAQ">TGTX</a>) sNDA for Ukoniq (umbralisib) tablets, and BLA for ublituximab injection. The proposed indication for these two products is in combination for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The committee will also discuss the existing umbralisib indications in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma approved under accelerated approval regulations.
<h3>Clinical Readouts/Presentations</h3>
ASCRS Meeting Presentation(s) 
Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>): Phase 2 data for OTX-DED, an intracanalicular dexamethasone Insert, for the treatment of episodic dry eye disease (Saturday, 3:30-3:35 pm ET)
<h3>Earnings</h3>
Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) (Tuesday, before the market open) 
Abbott Laboratories (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>) (Wednesday, before the market open) 
Plus Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pstv#NASDAQ">PSTV</a>) (Thursday, after the close) 
Intuitive Surgical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) (Thursday, after the close)
<h3>IPOs</h3>
IPO Quiet Period Expiry 
AN2 Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/antx#NASDAQ">ANTX</a>)
Related Link: <a href=" https://www.benzinga.com/general/biotech/22/03/26260100/merck-continues-to-see-executive-exodus-heres-a-look-at-all-recent-departures"> Merck Continues to See Executive Exodus; Here&#39;s A Look At All Recent Departures </a>

The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More

<h3>Gainers</h3>
<ul>
<li>Kaleido Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLDO#NASDAQ">KLDO</a>) stock increased by 10.3% to $0.32 during Thursday's after-market session. Today's trading volume for this security ended up closing at 14.2 million shares, which is 369.4 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $13.6 million. </li>
<li>NeuroBo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRBO#NASDAQ">NRBO</a>) shares moved upwards by 9.28% to $0.95. At the close, NeuroBo Pharmaceuticals's trading volume reached 232.9K shares. This is 119.9% of its average volume over the last 100 days. The company's market cap stands at $25.3 million. </li>
<li>ASLAN Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLN#NASDAQ">ASLN</a>) shares rose 9.14% to $0.82. The market value of their outstanding shares is at $57.1 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock moved upwards by 7.87% to $6.3. The company's market cap stands at $235.4 million. </li>
<li>Calyxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLXT#NASDAQ">CLXT</a>) stock rose 6.06% to $0.7. The company's market cap stands at $29.9 million. </li>
<li>aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFE#NASDAQ">LIFE</a>) shares increased by 6.06% to $5.25. The market value of their outstanding shares is at $145.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares fell 22.1% to $4.8 during Thursday's after-market session. Nektar Therapeutics's trading volume hit 1.3 million shares by close, accounting for 41.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $894.1 million. </li>
<li>InVivo Therapeutics Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVIV#NASDAQ">NVIV</a>) stock declined by 8.95% to $0.27. This security traded at a volume of 80.1K shares come close, making up 15.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $9.4 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock fell 8.36% to $0.35. The market value of their outstanding shares is at $11.6 million. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) stock declined by 6.64% to $0.47. The company's market cap stands at $10.3 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) shares declined by 6.33% to $1.63. This security traded at a volume of 519.1K shares come close, making up 525.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $96.7 million. </li>
<li>Immunogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMGN#NASDAQ">IMGN</a>) shares decreased by 5.43% to $5.06. The company's market cap stands at $1.1 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASLN

ATXI

CLXT

EVOK

GALT

IMGN

LIFE

NKTR

NRBO

NVIV

RNLX

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Kaleido Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLDO#NASDAQ">KLDO</a>) stock increased by 24.9% to $0.38 during Thursday's regular session. As of 13:30 EST, Kaleido Biosciences's stock is trading at a volume of 53.0 million, which is 1374.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.0 million. </li>
<li>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) stock moved upwards by 21.89% to $1.86. As of 13:30 EST, Verastem's stock is trading at a volume of 24.4 million, which is 1316.4% of its average full-day volume over the last 100 days. The company's market cap stands at $347.5 million. </li>
<li>Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) shares rose 19.06% to $3.31. The current volume of 2.2 million shares is 203.7% of Trevi Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $117.1 million. </li>
<li>Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) shares rose 15.85% to $3.8. As of 13:30 EST, this security is trading at a volume of 47.4 million shares, making up 82796.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.6 million. As per the press release, Q2 earnings came out 3 days ago. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares rose 15.37% to $0.69. Trading volume for Cellectar Biosciences's stock is 215.8K as of 13:30 EST. This is 110.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $42.4 million. </li>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares rose 14.66% to $7.16. As of 13:30 EST, Lyra Therapeutics's stock is trading at a volume of 262.0K, which is 144.2% of its average full-day volume over the last 100 days. The company's market cap stands at $93.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Histogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTO#NASDAQ">HSTO</a>) shares fell 32.4% to $0.26 during Thursday's regular session. The current volume of 13.6 million shares is 539.4% of Histogen's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $13.1 million. </li>
<li>Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) shares fell 20.97% to $20.17. Trading volume for this security as of 13:30 EST is 3.6 million, which is 495.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $976.5 million. </li>
<li>Lixte Biotech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock decreased by 18.88% to $1.59. Lixte Biotech Hldgs's stock is trading at a volume of 1.7 million shares as of 13:30 EST. This is 55.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.8 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares declined by 17.34% to $4.1. The current volume of 2.7 million shares is 96.5% of Biofrontera's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $70.1 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) stock declined by 14.84% to $3.86. The company's market cap stands at $126.7 million. </li>
<li>IsoPlexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISO#NASDAQ">ISO</a>) stock declined by 14.71% to $2.32. As of 13:30 EST, IsoPlexis's stock is trading at a volume of 91.8K, which is 116.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $90.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFRI

CLRB

HSTO

LEXX

LIXT

PTGX

PYXS

TRVI

VSTM

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

shares of low-float penny stock Kaleido Biosciences are trading higher on continued volatility after the company lasts week announced it intends to voluntarily delist its common stock.

Today&#39;s 5 Stock Ideas:
<ul>
<li>
Twitter (TWTR) - Shares were up ~6% near the $49 level following news Elon Musk made an offer to buy all of the company at $54.20 per share in cash. Analysts were mixed on the news; a Wedbush analyst, Dan Ives, was optimistic the offer would be accepted while another analyst voiced concern about Elon Musk walking away from the company if his offer was rejected.
</li>
</ul>
<ul>
<li>
Li Auto (LI) - A potential sympathy play following a <a href="https://twitter.com/Sino_Market/status/1514579625527365637">report</a> the CEO of peer in the Chinese electric vehicle space, XPeng (XPEV), warned all Chinese vehicle factories may have to stop production in May if supply chain disruption continues.
</li>
</ul>
<ul>
<li>
Safe-T Group (SFET) - A play on cybersecurity. Stocks in the group were on watch Wednesday following reports U.S. officials said advanced hackers have shown the ability to hijack multiple industrial control systems.
</li>
</ul>
<ul>
<li>
NanoViricides (NNVC) - A play on current fears related to bird flu contagion.
</li>
</ul>
<ul>
<li>
Kaleido Biosciences (KLDO) - One of Thursday morning&#39;s biggest winners. The company is a low-float penny-stock play. Shares closed up 75% on Wednesday and were up another 30% Thursday morning.
</li>
</ul>
&nbsp;
&nbsp;
Benzinga programming note: we&#39;ve started a podcast for the Stocks To Watch alert! Click <a href="https://www.benzinga.com/money/podcast-show/daily-stocks-to-watch/">here</a> to see all the episodes.
Hosted by the Benzinga Pro newsdesk&#39;s Brent Slava and Steve Krause, the podcast will give more in-depth information on the ideas presented in the daily Stocks To Watch alert!
Listeners can find the podcast on Spotify and Apple by searching &quot;Benzinga Stocks To Watch.&quot;

Pre-Market Outlook

NNVC

SFET

TWTR

Benzinga Pro's Top 5 Stocks To Watch For Thursday, Apr. 14, 2022: TWTR, LI, SFET, NNVC, KLDO

Kaleido Biosciences shares are trading higher on continue volatility after the company last week announced it intends to voluntarily delist its common stock.

<h3>Gainers</h3>
<ul>
<li>Kaleido Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLDO#NASDAQ">KLDO</a>) shares moved upwards by 105.3% to $0.35 during Wednesday's regular session. Kaleido Biosciences's stock is trading at a volume of 170.1 million shares as of 13:30 EST. This is 20116.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.0 million. </li>
<li>Antares Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRS#NASDAQ">ATRS</a>) shares increased by 49.19% to $5.58. As of 13:30 EST, this security is trading at a volume of 105.0 million shares, making up 13080.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $949.1 million. </li>
<li>Sierra Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRA#NASDAQ">SRRA</a>) stock rose 38.62% to $54.78. Trading volume for Sierra Oncology's stock is 8.6 million as of 13:30 EST. This is 694.2% of its average full-day volume over the last 100 days. The company's market cap stands at $1.2 billion. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares increased by 30.81% to $4.84. Biofrontera's stock is trading at a volume of 19.9 million shares as of 13:30 EST. This is 831.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $82.7 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Turning Point (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPTX#NASDAQ">TPTX</a>) stock moved upwards by 29.77% to $32.17. The current volume of 1.7 million shares is 338.3% of Turning Point's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $1.5 billion. </li>
<li>Exscientia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAI#NASDAQ">EXAI</a>) stock rose 21.01% to $14.95. Trading volume for Exscientia's stock is 176.3K as of 13:30 EST. This is 73.2% of its average full-day volume over the last 100 days. The company's market cap stands at $1.8 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NanoString Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSTG#NASDAQ">NSTG</a>) stock decreased by 31.3% to $22.65 during Wednesday's regular session. As of 13:30 EST, NanoString Technologies's stock is trading at a volume of 4.9 million, which is 950.6% of its average full-day volume over the last 100 days. The company's market cap stands at $1.0 billion. </li>
<li>PolarityTE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTE#NASDAQ">PTE</a>) shares fell 29.26% to $0.27. Trading volume for PolarityTE's stock is 21.2 million as of 13:30 EST. This is 404.2% of its average full-day volume over the last 100 days. The company's market cap stands at $24.3 million. </li>
<li>Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) shares declined by 20.26% to $13.07. Fulcrum Therapeutics's stock is trading at a volume of 1.4 million shares as of 13:30 EST. This is 283.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $531.1 million. </li>
<li>Bio-Path Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares fell 15.96% to $3.16. Trading volume for Bio-Path Holdings's stock is 251.6K as of 13:30 EST. This is 450.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.6 million. </li>
<li>Histogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTO#NASDAQ">HSTO</a>) shares declined by 15.89% to $0.35. The current volume of 10.8 million shares is 494.2% of Histogen's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $17.4 million. </li>
<li>Aeglea BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGLE#NASDAQ">AGLE</a>) shares decreased by 14.35% to $1.91. As of 13:30 EST, Aeglea BioTherapeutics's stock is trading at a volume of 1.0 million, which is 203.2% of its average full-day volume over the last 100 days. The company's market cap stands at $94.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGLE

ATRS

BPTH

EXAI

FULC

NSTG

TPTX

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares rose 19.6% to $1.22 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 223.2K shares, which is 17.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $109.9 million. </li>
<li>Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) shares increased by 18.74% to $0.22. At the close, Agile Therapeutics's trading volume reached 6.5 million shares. This is 341.7% of its average volume over the last 100 days. The company's market cap stands at $30.0 million. </li>
<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) shares moved upwards by 15.55% to $2.08. The market value of their outstanding shares is at $30.6 million. </li>
<li>Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) stock increased by 9.66% to $2.86. The market value of their outstanding shares is at $86.3 million. </li>
<li>Kaleido Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLDO#NASDAQ">KLDO</a>) shares rose 9.36% to $0.19. This security traded at a volume of 878.0K shares come close, making up 140.4% of its average volume over the last 100 days. The company's market cap stands at $8.0 million. </li>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) shares moved upwards by 7.04% to $0.26. The market value of their outstanding shares is at $37.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NanoString Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSTG#NASDAQ">NSTG</a>) stock decreased by 30.1% to $23.05 during Tuesday's after-market session. This security traded at a volume of 120.5K shares come close, making up 23.1% of its average volume over the last 100 days. The company's market cap stands at $1.0 billion. </li>
<li>Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) stock fell 11.96% to $5.45. Trading volume for this security closed at 70.0K, accounting for 14.4% of its average full-day volume over the last 100 days. The company's market cap stands at $285.7 million. </li>
<li>Histogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTO#NASDAQ">HSTO</a>) stock decreased by 11.32% to $0.37. Histogen's trading volume hit 6.5 million shares by close, accounting for 635.4% of its average volume over the last 100 days. The company's market cap stands at $18.4 million. </li>
<li>Berkeley Lights (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLI#NASDAQ">BLI</a>) shares declined by 8.98% to $5.55. The company's market cap stands at $375.6 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares decreased by 5.76% to $0.39. The market value of their outstanding shares is at $64.4 million. </li>
<li>Icosavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICVX#NASDAQ">ICVX</a>) shares decreased by 5.69% to $8.3. The company's market cap stands at $329.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGRX

ALZN

ANIX

BPTS

ICVX

LQDA

RGLS

TRVN

12 Health Care Stocks Moving In Tuesday's After-Market Session

Kaleido Biosciences shares are trading lower on continued momentum after the company announced it intends to voluntarily delist its common stock.

&nbsp;
<h3>Gainers</h3>
<ul>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares increased by 46.7% to $1.33 during Friday&#39;s regular session. As of 13:31 EST, Phio Pharma&#39;s stock is trading at a volume of 9.3 million, which is 1477.4% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $18.0 million.</li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares rose 21.72% to $0.25. Trading volume for this security as of 13:31 EST is 50.6 million, which is 399.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $31.2 million.</li>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares moved upwards by 16.31% to $5.03. Trading volume for Lyra Therapeutics&#39;s stock is 4.7 million as of 13:31 EST. This is 17197.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $65.3 million.</li>
<li>Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) shares rose 16.27% to $43.87. Bicycle Therapeutics&#39;s stock is trading at a volume of 808.0K shares as of 13:31 EST. This is 335.4% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $1.2 billion.</li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) shares moved upwards by 13.8% to $15.09. As of 13:31 EST, Nurix Therapeutics&#39;s stock is trading at a volume of 315.9K, which is 70.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $676.8 million. As per the press release, Q1 earnings came out yesterday.</li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) stock increased by 13.62% to $7.96. Ikena Oncology&#39;s stock is trading at a volume of 93.2K shares as of 13:31 EST. This is 70.5% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $287.6 million.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kaleido Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLDO#NASDAQ">KLDO</a>) shares decreased by 69.9% to $0.45 during Friday&#39;s regular session. Trading volume for this security as of 13:31 EST is 8.1 million, which is 8174.5% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $18.9 million.</li>
<li>Genocea Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNCA#NASDAQ">GNCA</a>) stock decreased by 51.71% to $0.63. Genocea Biosciences&#39;s stock is trading at a volume of 1.0 million shares as of 13:31 EST. This is 642.2% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $36.8 million.</li>
<li>C4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCC#NASDAQ">CCCC</a>) stock decreased by 48.83% to $11.72. The current volume of 590.5K shares is 105.5% of C4 Therapeutics&#39;s average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $571.2 million.</li>
<li>Rubius Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUBY#NASDAQ">RUBY</a>) stock declined by 41.86% to $3.41. As of 13:31 EST, Rubius Therapeutics&#39;s stock is trading at a volume of 2.6 million, which is 341.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $307.2 million.</li>
<li>BioCryst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) stock decreased by 37.39% to $11.2. Trading volume for this security as of 13:31 EST is 27.0 million, which is 669.2% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $2.0 billion.</li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares decreased by 25.05% to $9.28. Trading volume for Nutex Health&#39;s stock is 972.4K as of 13:31 EST. This is 113.8% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $5.9 billion. See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

Intraday Update

Markets

BCRX

BCYC

CCCC

GNCA

IKNA

NRIX

NUTX

PHIO

RUBY

XCUR

12 Health Care Stocks Moving In Friday's Intraday Session

Options

ACIW

AFIB

AGFY

AKBA

ALGS

ALLR

ALNA

ANGI

ANNX

ASTE

ATHX

ATNF

AXDX

AZEK

BBCP

BEAM

BJRI

BNED

BOLT

Borqs Technologies, Inc. - Ordinary Shares

BRQS

CELC

Eaton Vance California Municipal Income Trust

COSM

CPTN

CRBU

CREX

CTHR

CTLP

CULP

CURI

DAIO

DBTX

DENN

DRUG

EBET

ENFN

ERAS

ETNB

EVFM

EXPI

FCAP

FIXX

FREQ

FSRD

FTHM

FWBI

GHLD

GRPH

HGBL

HLTH

INFU

ISPO

IXHL

KLTR

LCFY

LFUS

LIQT

LLAP

Blackrock Muniholdings Investment Quality Fund

MHLD

Blackrock Muniholdings New York Quality Fund

Airspan Networks Holdings Inc. Common Stock

MIMO

MTEK

Blackrock Muniholdings California Quality Fund

Stocks That Hit 52-Week Lows On Friday

<ul>
<li>Kaleido Biosciences Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kldo#NASDAQ">KLDO</a>) has <a class="editor-rtfLink" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001751299/000119312522099802/d329248d8k.htm" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">delivered formal notice to voluntarily delist</a>&nbsp;its common stock from NASDAQ as the Company will stop all operations.</li>
<li>The Company expects to file a Form 25 with the Securities and Exchange Commission by April 18 to effect the voluntary delisting effective by April 28.</li>
<li>The Board of Directors voted to immediately wind down and cease all of the Company&rsquo;s ongoing operations.&nbsp;</li>
<li>Related:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/22/01/25302145/kaleido-halts-upcoming-phase-2-copd-trial-piper-sandler-cuts-price-target" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Kaleido Halts Upcoming Phase 2 COPD Trial, Piper Sandler Cuts Price Target</a>.</li>
<li>In connection with the cessation of activities, the employment of all of the Company&rsquo;s remaining employees was terminated effective immediately.&nbsp;</li>
<li>As previously announced, the Company had initiated a strategic process, but it did not result in the identification of any viable transactions, given its limited remaining resources.</li>
<li>The Company cannot continue operations and believes that the best alternative is an orderly wind-down process.&nbsp;</li>
<li>Price Action:&nbsp;KLDO shares are down 74.9% at $0.37 during the market session on the last check Friday.</li>
</ul>

Kaleido Biosciences Shares Halted Again On Circuit Breaker To Downside; Down 75%

Kaleido Biosciences Shares Resume Trading, Down 75%

Kaleido Biosciences Shares Resume Trading, Down 73%

Kaleido Biosciences Shares Halted On Circuit Breaker To Downside

Kaleido Biosciences Shares Resume Trading; Down 50%

Kaleido Biosciences Announces Notice Of Voluntary Delisting Of Common Stock

Kaleido Biosciences Shares Halted On Code News Pending

<h3>Upgrades</h3>
According to Scotiabank, the prior rating for Welltower Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) was changed from Sector Perform to Sector Outperform. In the fourth quarter, Welltower showed an EPS of $0.83, compared to $0.84 from the year-ago quarter. The stock has a 52-week-high of $98.47 and a 52-week-low of $70.74. At the end of the last trading period, Welltower closed at $97.82. 
According to B of A Securities, the prior rating for SunPower Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) was changed from Underperform to Neutral. In the fourth quarter, SunPower showed an EPS of $0.07, compared to $0.14 from the year-ago quarter. At the moment, the stock has a 52-week-high of $35.00 and a 52-week-low of $14.00. SunPower closed at $21.41 at the end of the last trading period. 
For Leslies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>), Goldman Sachs upgraded the previous rating of Neutral to Buy. For the first quarter, Leslies had an EPS of $0.06, compared to year-ago quarter EPS of $0.06. The current stock performance of Leslies shows a 52-week-high of $31.55 and a 52-week-low of $18.14. Moreover, at the end of the last trading period, the closing price was at $20.15. 
For Ollie's Bargain Outlet Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. For the fourth quarter, Ollie's Bargain Outlet had an EPS of $0.69, compared to year-ago quarter EPS of $0.97. At the moment, the stock has a 52-week-high of $98.58 and a 52-week-low of $37.67. Ollie's Bargain Outlet closed at $42.85 at the end of the last trading period. 
For NIO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), UBS upgraded the previous rating of Neutral to Buy. NIO earned $0.16 in the fourth quarter, compared to $0.14 in the year-ago quarter. The current stock performance of NIO shows a 52-week-high of $55.13 and a 52-week-low of $13.01. Moreover, at the end of the last trading period, the closing price was at $21.93. 
Evercore ISI Group upgraded the previous rating for DCP Midstream LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCP#NYSE">DCP</a>) from In-Line to Outperform. In the fourth quarter, DCP Midstream showed an EPS of $1.44, compared to $0.34 from the year-ago quarter. The stock has a 52-week-high of $36.71 and a 52-week-low of $21.32. At the end of the last trading period, DCP Midstream closed at $33.16. 
JP Morgan upgraded the previous rating for Zebra Technologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) from Neutral to Overweight. Zebra Technologies earned $4.54 in the fourth quarter, compared to $4.46 in the year-ago quarter. The current stock performance of Zebra Technologies shows a 52-week-high of $615.00 and a 52-week-low of $375.63. Moreover, at the end of the last trading period, the closing price was at $413.73. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
<h3>Downgrades</h3>
Chardan Capital downgraded the previous rating for Kaleido Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLDO#NASDAQ">KLDO</a>) from Buy to Neutral. For the third quarter, Kaleido Biosciences had an EPS of $0.54, compared to year-ago quarter EPS of $0.65. The current stock performance of Kaleido Biosciences shows a 52-week-high of $9.47 and a 52-week-low of $1.30. Moreover, at the end of the last trading period, the closing price was at $1.70. 
JP Morgan downgraded the previous rating for Gold Fields Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) from Overweight to Neutral. NoneThe current stock performance of Gold Fields shows a 52-week-high of $17.20 and a 52-week-low of $7.75. Moreover, at the end of the last trading period, the closing price was at $16.12. 
B of A Securities downgraded the previous rating for Sportradar Group AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) from Buy to Neutral. At the moment, the stock has a 52-week-high of $28.22 and a 52-week-low of $11.06. Sportradar Gr closed at $16.65 at the end of the last trading period. 
According to Argus Research, the prior rating for PPL Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) was changed from Buy to Hold. PPL earned $0.22 in the fourth quarter, compared to $0.59 in the year-ago quarter. The current stock performance of PPL shows a 52-week-high of $30.71 and a 52-week-low of $25.27. Moreover, at the end of the last trading period, the closing price was at $29.02. 
Citigroup downgraded the previous rating for Quest Diagnostics Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) from Buy to Neutral. For the fourth quarter, Quest Diagnostics had an EPS of $3.33, compared to year-ago quarter EPS of $4.48. At the moment, the stock has a 52-week-high of $174.16 and a 52-week-low of $125.69. Quest Diagnostics closed at $136.33 at the end of the last trading period. 
According to Citigroup, the prior rating for Avantor Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) was changed from Buy to Neutral. For the fourth quarter, Avantor had an EPS of $0.36, compared to year-ago quarter EPS of $0.29. At the moment, the stock has a 52-week-high of $44.37 and a 52-week-low of $29.01. Avantor closed at $34.19 at the end of the last trading period. 
Loop Capital downgraded the previous rating for Crocs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) from Buy to Hold. In the fourth quarter, Crocs showed an EPS of $2.15, compared to $1.06 from the year-ago quarter. The current stock performance of Crocs shows a 52-week-high of $183.88 and a 52-week-low of $66.50. Moreover, at the end of the last trading period, the closing price was at $75.73. 
For WD-40 Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>), DA Davidson downgraded the previous rating of Neutral to Underperform. In the first quarter, WD-40 showed an EPS of $1.34, compared to $1.72 from the year-ago quarter. At the moment, the stock has a 52-week-high of $321.41 and a 52-week-low of $182.11. WD-40 closed at $185.01 at the end of the last trading period. 
For Brookfield Renewable Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEP#NYSE">BEP</a>), TD Securities downgraded the previous rating of Buy to Hold. For the fourth quarter, Brookfield Renewable had an EPS of $0.12, compared to year-ago quarter EPS of $0.37. At the moment, the stock has a 52-week-high of $44.30 and a 52-week-low of $30.93. Brookfield Renewable closed at $40.97 at the end of the last trading period. 
For Duck Creek Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCT#NASDAQ">DCT</a>), Wolfe Research downgraded the previous rating of Outperform to Peer Perform. In the second quarter, Duck Creek Technologies showed an EPS of $0.04, compared to $0.01 from the year-ago quarter. At the moment, the stock has a 52-week-high of $50.90 and a 52-week-low of $18.60. Duck Creek Technologies closed at $19.04 at the end of the last trading period. 
According to Goldman Sachs, the prior rating for Silverback Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBTX#NASDAQ">SBTX</a>) was changed from Buy to Neutral. Silverback Therapeutics earned $0.67 in the fourth quarter, compared to $1.37 in the year-ago quarter. At the moment, the stock has a 52-week-high of $46.55 and a 52-week-low of $3.06. Silverback Therapeutics closed at $3.21 at the end of the last trading period. 
RBC Capital downgraded the previous rating for LHC Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHCG#NASDAQ">LHCG</a>) from Outperform to Sector Perform. In the fourth quarter, LHC Group showed an EPS of $1.26, compared to $1.40 from the year-ago quarter. The stock has a 52-week-high of $223.63 and a 52-week-low of $108.42. At the end of the last trading period, LHC Group closed at $168.13. 
For Hologic Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), Evercore ISI Group downgraded the previous rating of Outperform to In-Line. Hologic earned $2.17 in the first quarter, compared to $2.86 in the year-ago quarter. The stock has a 52-week-high of $81.04 and a 52-week-low of $60.10. At the end of the last trading period, Hologic closed at $76.93. 
For Hercules Capital Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>), Piper Sandler downgraded the previous rating of Overweight to Neutral. Hercules Capital earned $0.35 in the fourth quarter, compared to $0.37 in the year-ago quarter. At the moment, the stock has a 52-week-high of $18.61 and a 52-week-low of $15.91. Hercules Capital closed at $18.57 at the end of the last trading period. 
According to Goldman Sachs, the prior rating for Baxter International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) was changed from Neutral to Sell. Baxter Intl earned $1.04 in the fourth quarter, compared to $0.80 in the year-ago quarter. The stock has a 52-week-high of $89.70 and a 52-week-low of $73.12. At the end of the last trading period, Baxter Intl closed at $78.58. 
Evercore ISI Group downgraded the previous rating for Enterprise Products Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) from Outperform to In-Line. For the fourth quarter, Enterprise Prods Partners had an EPS of $0.47, compared to year-ago quarter EPS of $0.15. The current stock performance of Enterprise Prods Partners shows a 52-week-high of $26.18 and a 52-week-low of $20.42. Moreover, at the end of the last trading period, the closing price was at $25.86. 
William Blair downgraded the previous rating for Blend Labs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) from Outperform to Market Perform. At the moment, the stock has a 52-week-high of $21.04 and a 52-week-low of $4.45. Blend Labs closed at $4.80 at the end of the last trading period. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
<h3>Initiations</h3>
With a Positive rating, Susquehanna initiated coverage on Shift4 Payments Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>). The price target seems to have been set at $97.00 for Shift4 Payments. In the fourth quarter, Shift4 Payments showed an EPS of $0.08, compared to $0.05 from the year-ago quarter. At the moment, the stock has a 52-week-high of $104.11 and a 52-week-low of $38.88. Shift4 Payments closed at $63.54 at the end of the last trading period. 
BTIG initiated coverage on Gracell Biotechnologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRCL#NASDAQ">GRCL</a>) with a Buy rating. The price target for Gracell Biotechnologies is set to $18.00. For the fourth quarter, Gracell Biotechnologies had an EPS of $0.30, compared to year-ago quarter EPS of $0.75. At the moment, the stock has a 52-week-high of $19.74 and a 52-week-low of $1.68. Gracell Biotechnologies closed at $2.24 at the end of the last trading period. 
With an Underperform rating, B of A Securities initiated coverage on Patrick Industries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>). The price target seems to have been set at $60.00 for Patrick Industries. For the fourth quarter, Patrick Industries had an EPS of $2.62, compared to year-ago quarter EPS of $1.64. The stock has a 52-week-high of $98.83 and a 52-week-low of $59.53. At the end of the last trading period, Patrick Industries closed at $61.21. 
With an Outperform rating, SVB Leerink initiated coverage on Alignment Healthcare Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>). The price target seems to have been set at $19.00 for Alignment Healthcare. The stock has a 52-week-high of $28.59 and a 52-week-low of $6.14. At the end of the last trading period, Alignment Healthcare closed at $11.72. 
Morgan Stanley initiated coverage on Marqeta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) with a Equal-Weight rating. The price target for Marqeta is set to $15.00. For the fourth quarter, Marqeta had an EPS of $0.07, compared to year-ago quarter EPS of $0.11. The current stock performance of Marqeta shows a 52-week-high of $37.90 and a 52-week-low of $8.24. Moreover, at the end of the last trading period, the closing price was at $11.10. 
Needham initiated coverage on Fast Radius Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSRD#NASDAQ">FSRD</a>) with a Buy rating. The price target for Fast Radius is set to $4.00. The stock has a 52-week-high of $8.36 and a 52-week-low of $1.34. At the end of the last trading period, Fast Radius closed at $1.38. 
With an Overweight rating, Piper Sandler initiated coverage on DigitalOcean Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>). The price target seems to have been set at $72.00 for DigitalOcean Holdings. The stock has a 52-week-high of $133.40 and a 52-week-low of $35.35. At the end of the last trading period, DigitalOcean Holdings closed at $59.57. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Comments

Kaleido Biosciences

Kaleido Biosciences (KLDO) Forecast

Kaleido Biosciences (OTC:KLDO) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga